GC
BIIB icon

Grimes & Company’s Biogen BIIB Stock Holding History

Grimes & Company’s Portfolio BIIB Stock Details BIIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.32M Sell
33,877
-807
-2% -$154K 0.16% 94
2026
Q1 		$6.36M Buy
34,684
+840
+2% +$155K 0.18% 99
2025
Q4 		$5.96M Sell
33,844
-1,453
-4% -$237K 0.14% 104
2025
Q3 		$4.94M Sell
35,297
-5,727
-14% -$774K 0.12% 116
2025
Q2 		$5.15M Sell
41,024
-18,310
-31% -$2.28M 0.14% 112
2025
Q1 		$8.12M Buy
59,334
+33,721
+132% +$4.82M 0.25% 86
2024
Q4 		$3.92M Sell
25,613
-21,854
-46% -$3.69M 0.11% 110
2024
Q3 		$9.2M Sell
47,467
-273
-0.6% -$57.1K 0.25% 82
2024
Q2 		$11.1M Buy
47,740
+852
+2% +$185K 0.33% 69
2024
Q1 		$10.1M Buy
46,888
+1,689
+4% +$396K 0.31% 76
2023
Q4 		$11.7M Buy
45,199
+629
+1% +$154K 0.39% 60
2023
Q3 		$11.5M Buy
44,570
+486
+1% +$130K 0.44% 54
2023
Q2 		$12.6M Sell
44,084
-404
-0.9% -$120K 0.45% 51
2023
Q1 		$12.4M Sell
44,488
-1,547
-3% -$428K 0.51% 48
2022
Q4 		$12.7M Sell
46,035
-686
-1% -$194K 0.54% 40
2022
Q3 		$12.5M Buy
46,721
+595
+1% +$126K 0.65% 32
2022
Q2 		$9.41M Buy
46,126
+938
+2% +$192K 0.47% 49
2022
Q1 		$9.52M Buy
45,188
+3,659
+9% +$796K 0.5% 62
2021
Q4 		$9.96M Sell
41,529
-312
-0.7% -$80.2K 0.46% 60
2021
Q3 		$11.8M Sell
41,841
-13
-0% -$4.26K 0.52% 52
2021
Q2 		$14.5M Sell
41,854
-197
-0.5% -$59.7K 0.63% 45
2021
Q1 		$11.8M Buy
42,051
+3,341
+9% +$901K 0.57% 50
2020
Q4 		$9.48M Buy
38,710
+3,010
+8% +$776K 0.49% 57
2020
Q3 		$10.1M Buy
35,700
+3,506
+11% +$978K 0.65% 45
2020
Q2 		$8.61M Sell
32,194
-195
-0.6% -$58.6K 0.6% 52
2020
Q1 		$10.2M Sell
32,389
-328
-1% -$99.5K 0.94% 20
2019
Q4 		$9.71M Sell
32,717
-5,239
-14% -$1.45M 0.64% 44
2019
Q3 		$8.84M Buy
37,956
+36,196
+2,057% +$8.43M 0.63% 43
2019
Q2 		$412K Sell
1,760
-1,000
-36% -$231K 0.03% 186
2019
Q1 		$653K Buy
2,760
+1,000
+57% +$315K 0.05% 143
2018
Q4 		$530K Sell
1,760
-292
-14% -$93.2K 0.05% 144
2018
Q3 		$725K Buy
2,052
+92
+5% +$31.7K 0.06% 136
2018
Q2 		$569K Buy
1,960
+630
+47% +$177K 0.05% 157
2018
Q1 		$364K Sell
1,330
-35
-3% -$10.9K 0.04% 176
2017
Q4 		$435K Hold
1,365
– – 0.04% 156
2017
Q3 		$427K Hold
1,365
– – 0.05% 147
2017
Q2 		$370K Hold
1,365
– – 0.04% 154
2017
Q1 		$373K Hold
1,365
– – 0.04% 155
2016
Q4 		$387K Hold
1,365
– – 0.04% 148
2016
Q3 		$427K Sell
1,365
-220
-14% -$65.2K 0.06% 138
2016
Q2 		$383K Hold
1,585
– – 0.05% 141
2016
Q1 		$413K Buy
1,585
+140
+10% +$37K 0.05% 130
2015
Q4 		$443K Sell
1,445
-38
-3% -$10.9K 0.06% 126
2015
Q3 		$433K Sell
1,483
-200
-12% -$66K 0.06% 121
2015
Q2 		$680K Buy
1,683
+140
+9% +$56.2K 0.1% 103
2015
Q1 		$652K Buy
1,543
+4
+0.3% +$1.58K 0.16% 87
2014
Q4 		$522K Sell
1,539
-38
-2% -$12.3K 0.13% 99
2014
Q3 		$522K Buy
1,577
+50
+3% +$16.5K 0.14% 95
2014
Q2 		$481K Buy
1,527
+349
+30% +$105K 0.13% 97
2014
Q1 		$360K Buy
1,178
+215
+22% +$68.2K 0.1% 106
2013
Q4 		$269K Hold
963
– – 0.08% 111
2013
Q3 		$232K Buy
+963
New +$216K 0.08% 116

Other funds holding BIIB

Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return
AIM
Artemis Investment Management Edinburgh, United Kingdom $11.2B AUM 80.72% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
AAMU
AEGON Asset Management (UK) Edinburgh, United Kingdom $9.38B AUM 48.94% 1-Year Est. Return
New York State Teachers Retirement System (NYSTRS)
New York State Teachers Retirement System (NYSTRS) Albany, New York $54.2B AUM 43.77% 1-Year Est. Return
ECSS
Eurizon Capital SGR SpA Milan $37.3B AUM
ADEF
Adams Diversified Equity Fund Baltimore, Maryland $3.27B AUM 45.57% 1-Year Est. Return
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return

Grimes & Company's BIIB Position: Q2 2026 in Review

Grimes & Company reduced its Biogen (BIIB) stake by 2.3% in Q2 2026, selling an estimated $154K and leaving 33,877 shares worth $7.32M. The position accounts for 0.16% of the portfolio, ranked #94.

Grimes & Company first reported a position in BIIB in Q3 2013 and has held it in 52 quarters since. The position peaked at $14.5M in Q2 2021. 380 funds tracked by Wall St. Rank hold BIIB as of Q2 2026.

  • Grimes & Company held 33,877 shares of Biogen worth $7.32M as of Q2 2026.
  • Grimes & Company sold 807 Biogen shares in Q2 2026, an estimated $154K.
  • Biogen made up 0.16% of Grimes & Company's portfolio in Q2 2026, its #94 holding.
  • Grimes & Company first reported a position in Biogen in Q3 2013 and has held it in 52 quarters since.
  • Grimes & Company's Biogen position peaked at $14.5M in Q2 2021.
  • 380 funds tracked by Wall St. Rank held Biogen as of Q2 2026.

Based on Grimes & Company's 13F filing for Q2 2026, filed 17 Jul 2026.